Intense Exercise & Potential Heart Damage (aka Athlete's Heart)

Galpin emphasizes that the biggest signal for risk is familial or genetic inheritance. He shares the story of Joel Jameson, who had a 50% blockage in his widowmaker artery despite a V2 max over 55, no symptoms, and normal blood work. Joel's mother had a stroke at 60, his father died early, his uncle died early, and his brother had a triple bypass before 50. Galpin himself has multiple uncles and great-uncles who died of heart disease, and he resisted screening for years because he felt healthy. He now believes that attitude is a mistake. He recommends starting with the American Heart Association's free 12-step screening questionnaire, then progressing to imaging if indicated.

Galpin explains that because exercise-induced cardiac remodeling (EICR) and pathological hypertrophy can look identical on imaging, the only way to determine the cause is to remove the stimulus. If the heart size decreases after 3 months of no exercise, it suggests the enlargement was adaptive. If it doesn't, it's more likely a genetic cardiomyopathy. He acknowledges that 3 months without exercise sounds terrible to athletes, but it's a small price to pay to rule out a potentially fatal condition. He notes that this is the most common protocol used by cardiologists when they see an athlete with an enlarged heart.

Galpin explains that functional adaptations like increased V2 max and stroke volume can happen with very little exercise—even 'exercise snacks' like brief bodyweight circuits. However, actual changes in heart size and structure require a consistent stimulus of about 4-8 hours per week for many months to years. He cites studies showing that initial remodeling is concentric, and with sustained exposure, eccentric remodeling (chamber dilation) occurs. He suggests that if someone is concerned about risk, they could hedge by keeping exercise to around an hour a day, which is still far more than most people do. He emphasizes that this is not a hard rule but a general guideline based on the literature.

Galpin notes that the most susceptible sports appear to be rowing, running, cycling, swimming, and skiing. He also mentions a specific signal in basketball, where black male athletes have a sudden cardiac death rate of about 1 in 4,000, compared to 1 in 16,000 for all black male college athletes. He suggests this may warrant targeted screening, though he acknowledges the data is limited and it's unclear if it's something specific to basketball or just an artifact. He recommends this as a reasonable precaution, not a mandate.

Andy Galpin was present at that 2012 ACSM meeting and recalls the presentation. He emphasizes that the authors themselves did not frame the data as showing danger, but the narrative took off. He notes that every few years, a new wave of articles appears claiming exercise is harmful, often triggered by a high-profile death or a case study. The Cooper Clinic study followed 14,000 runners for an average of 15 years, and while those running more than 20 miles/week didn't have a statistically significant increase in survival compared to non-runners, they also didn't have a higher mortality rate. Galpin argues that the appropriate interpretation is that most running is excellent for health, and beyond 20 miles/week, it's not more advantageous but not harmful either. He stresses that scientists must ensure conclusions match the data to avoid public misinformation.

Galpin explains that most genetic studies in this area have looked for single-point mutations, and while some cardiomyopathies may have a single genetic error, it's not consistent across individuals. He has seen companies selling tests based on these early findings, but he believes it's too early to draw conclusions. He also notes that even the categorization of ancestry in these studies is imprecise, often using broad 'white' vs. 'black' labels that obscure true genetic diversity. He hopes the field will move toward more specific subgroup analyses, but for now, he advises against relying on genetic testing to rule out risk.

Galpin explains that the same adaptations that improve stroke volume—increased vagal tone and a more relaxed, compliant heart—also predispose athletes to AFib. The atria become larger and the valves may not shut as tightly, causing a little backflow and fluttering. He cites a Swedish cross-country skier study where faster skiers (proxy for more training) had a 1.3x greater risk of AFib, and those who completed more than five races had an additional 1.3x risk. Some experts estimate up to a 5x higher risk of AFib in lifelong high-intensity endurance athletes. However, he stresses that these athletes have almost zero other health risk factors, and the overall mortality risk is still dramatically lower than sedentary individuals. He also notes that the data is predominantly in men, and women may not have the same risk profile.

Galpin discusses a Cooper Clinic study of over 20,000 people followed for decades. Those with higher CAC scores had more heart attacks, but they also had lower all-cause mortality. He interprets this as fitness allowing people to 'get away with' some anatomical changes that would otherwise be problematic. He also cites Ben Levine's work showing that people doing more than 3,000 minutes of exercise per week (about 30 miles of running at a 10-minute pace) had increased CAC prevalence but no increased cardiovascular disease risk after a decade of follow-up, even with clinically significant coronary artery scores. Galpin notes that radiologists and cardiologists are often unsure how to handle these findings in athletes, and many default to treating with statins out of caution. He emphasizes that this is a genuine area of controversy, unlike the 20-mile misinterpretation.

He shares the story of his friend Joel Jameson, a world-renowned endurance expert with a V2 max over 55, who at age 40 discovered a 50% blockage in his widowmaker artery despite having no symptoms, normal blood work, and a healthy lifestyle. Joel's family history included a mother's stroke at 60, a father's early death, and a brother's triple bypass before 50. This story, combined with his own family history, finally convinced Galpin to get a coronary CT angiogram, which cost about $1,200 out-of-pocket. He emphasizes that blood work and ECGs are not sufficient; you need imaging to see structural issues. He also mentions the American Heart Association's free 12-step screening questionnaire as a starting point.